LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/06/2025
Voltar para busca
Dado oficial do USPTO
TIGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TIGEN
ST13
US500000079304640Classe
1, 5, 10, 42, 44
Pedido
79304640
Registro
6674502
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
14/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 10, 42, 44
Data de depósito
13/11/2020
Data de registro
22/03/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/03/2022
Última transação
14/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
33
Localização do titular
CH
Examinador
BLAZICH,JOAN MICHELE
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Tigen Pharma SA
Representantes
Stacey Halpern Knobbe, Martens, Olson & Bear, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in industry and science; chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in the development being the manufacturemanufacture of reagents for industrial or scientific use; chemicalbiochemicalbiological and biotechnological preparationspolypeptides or proteinsfor use of laboratoriesdiagnostics and analyses for industrial or scientific use; chemicalbiochemicalbiological and biotechnological substancespolypeptides and proteinsfor use in the manufacture of pharmaceuticals
Classe 5
Pharmaceutical products and medical preparationsgene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseasesgenetic diseasesautoimmune diseases and infectious diseases
Classe 10
Medical instrumentsequipment and apparatusinstrumentsequipment and apparatus for cell and cell material collectionthawingwashingselectionexpansionmodificationharvestingfinal formulationfreezingstorage and infusion into a patient in the fields of genetic diseasesautoimmune diseasesinfectious diseaseslocalized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions
Classe 42
Scientific researchtechnological development of new products for third parties; medical research; scientific and industrial research in biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific servicesdevelopment of medicinesactive substances and vaccines; scientific servicesdevelopment of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; upgradingmaintenance and rental of computer software; updatingmaintenance and rental of computer software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process developmentmanufacturingqualitysupply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; chemical and biological laboratory services
Classe 44
Medical services; pharmacy advice servicespharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/06/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
31/12/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/09/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/08/2022
FIMP
FINAL DISPOSITION PROCESSED
15/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
22/03/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/01/2022
PUBO
PUBLISHED FOR OPPOSITION
04/01/2022
GPNX
NOTIFICATION PROCESSED BY IB
01/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/12/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
15/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/11/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
29/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
29/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/11/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/11/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/11/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/08/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
20/08/2021
RFNT
REFUSAL PROCESSED BY IB
31/05/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/05/2021
RFRR
REFUSAL PROCESSED BY MPU
07/05/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/05/2021
CNRT
NON-FINAL ACTION WRITTEN
03/05/2021
DOCK
ASSIGNED TO EXAMINER
24/04/2021
MAFR
APPLICATION FILING RECEIPT MAILED
23/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/02/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/02/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TIGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.